Diabetic neuropathy - A continuing enigma

Diabetes/Metabolism Research and Reviews

Volumn 16, Issue 6, 2000, Pages 408-433

  Sugimoto, K ^a   Murakawa, Y ^a   Sima, A A F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Classification; Clinical management; Clinical trials; Neuropathy; Pathogenesis; Pathology; Prevalence; Signs and symptoms

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; GAMMA LINOLENIC ACID; NERVE GROWTH FACTOR; PROSTAGLANDIN; THIOCTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE CLASSIFICATION; HUMAN; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STAGING; SYMPTOM;

ANIMALS; CLINICAL TRIALS; DIABETIC RETINOPATHY; HUMANS; POLYNEUROPATHIES; PREVALENCE;

EID: 0034513543     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-7560(200011/12)16:6<408::AID-DMRR158>3.0.CO;2-R     Document Type: Review

References (402)

1. Ellenberg and Rifkin diabetic neuropathy
2. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973
3. Diabetic neuropathies
4. Pathological definition and evaluation of diabetic neuropathy and clinical correlations
5. Diabetic neuropathies
6. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy
7. Complications: Neuropathy, pathogenetic considerations
8. Role of hypoxia, Oxidative stress, and excitatory neurotoxins in diabetic neuropathy
9. Metabolic alterations of peripheral nerve in diabetes
10. C-Peptide revisited - New physiological effects and therapeutic implications
11. Experimental diabetic neuropathy: An update
12. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
13. Diagnosis, staging and epidemiology of diabetic peripheral neuropathy
14. Peripheral diabetic neuropathy: Current recommendations and future prospects for its prevention and management
15. Diagnosis and management of diabetic peripheral neuropathy
16. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study
17. The neuropathy study group of the Italian Society for the Study of Diabetes: Prevalence of neuropathy in IDDM patients in Piemonte, Italy
18. Epidemiological correlates of diabetic neuropathy: Report from Pittsburgh Epidemiology of Diabetes Complications Study
19. A multicenter study on the prevalence of diabetic neuropathy in Italy
20. A multicenter study on the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population
21. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers
22. Diabetic polyneuropathy
23. Severe early-onset polyneuropathy in insulin-dependent diabetes mellitus. A clinical and pathological study
24. Progressive centripetal degeneration of axons in small fibre diabetic polyneuropathy
25. The Ponalrestat Study Group. Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial
26. Design of controlled clinical trials for diabetic polyneuropathy
27. Morphologie der peripheren diabetischen neuropathie und ihre korrelation mit funktionstesten
28. Structural-functional interactions in the therapeutic response of diabetic neuropathy
29. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy
30. Overt diabetic neuropathy: Repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity
31. Quantitative sensory testing: A consensus report from the Peripheral Neuropathy Association
32. Pain due to peripheral nerve damage: A hypothesis
33. Pain in peripheral neuropathy related to rate and kind of fiber degeneration
34. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration
35. Painful diabetic neuropathy. A morphometric study
36. Spontaneous activity of primary afferent neurons in diabetic BB-Wistar rats: A possible mechanism of chronic diabetic pain
37. Mechanisms and treatment of pain
38. The natural history of acute painful diabetic polyneuropathy
39. Acute painful diabetic neuropathy following severe weight loss
40. Diabetic neuropathic cachexia
41. Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an aldose reductase inhibitor
42. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
43. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies
44. Quantitation of epidermal nerves in diabetic neuropathy
45. Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves
46. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort
47. The assessment of diabetic polyneuropathy in daily clinical practice: Reproducibility and validity of Semmes Weinstein monofilaments examination and clinical neurological examination
48. American Diabetes Association: Consensus statement Report and recommendations of the San Antonio Conference on Diabetic Neuropathy American Diabetes Association American Academy of Neurology
49. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy
50. A multicenter study on the prevalence of diabetic neuropathy in Italy
51. Neuropathology of diabetic neuropathy and its correlations with neurophysiology
52. Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the Early Diabetes Intervention Trial (EDIT)
53. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
54. The effect of 8 years of strict glycemic control on peripheral nerve function in IDDM patients: The Oslo Study
55. The effect of intensive diabetes therapy on the development and progression of neuropathy
56. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 32)
57. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus
58. C-Peptide prevents nodal and paranodal structural and molecular changes in Type 1 diabetic neuropathy
59. Antidepressants in the treatment of diabetic neuropathy symptoms. Pharmacodynamic, kinetic and generic aspects
60. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy
61. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol®): Double fluid crossover trial
62. Mexeletine in the treatment of diabetic neuropathy
63. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study
64. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy
65. Preventive effect of long-term aldose reductase inhibition (Ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic BB-rat
66. Increased regeneration in ARI-treated diabetic nerve is associated with upregulation of IGF-1 and NGF receptors
67. Diabetic neuropathy - The utility of nerve biopsy
68. Aldose reductase inhibitors: The end of an era or the need for different trial designs?
69. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy
70. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients
71. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy
72. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy
73. Limited benefits of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: A 24-week controlled trial
74. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy
75. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy
76. Diabetic neuropathy in the upper limb and the effects of twelve months sorbinil treatment
77. Aldose reductase inhibition in diabetic neuropathy: Clinical and neurophysiological studies of one year's treatment with sorbinil
78. Improvement in peripheral nerve function after one year of Sorbinil
79. Endoneurial microvessels in human diabetic neuropathy: Endothelial cell dysjunction and look of treatment effect by aldose reductase inhibitor
80. Autonomic and peripheral nerve function in early diabetic neuropathy
81. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy
82. A 12 month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy
83. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months
84. One-year treatment with aldose reductase inhibitor, ponalrestat, in diabetic neuropathy
85. A multicenter trial of the aldose reductase inhibitor tolrestat in patients with symptomatic diabetic neuropathy
86. A multicenter trial of the aldose reductase inhibitor tolrestat in patients with symptomatic diabetic peripheral neuropathy
87. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy
88. Tolrestat for mild diabetic neuropathy
89. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effect on nerve function
90. A placebo-controlled double-blind study of epalrestat (ono-2235) in patients with diabetic neuropathy
91. Aminoguanidine effect on nerve blood flow, vascular permeability, electrophysiology and oxygen free radicals
92. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats
93. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats
94. Design and baseline characteristics for the aminoguanidine clinical trial in overt Type 2 diabetic nephropathy (ACTION II)
95. The effects of gamma-linoleic acid on human diabetic peripheral neuropathy: A double-blind, placebo controlled trial
96. Treatment of diabetic neuropathy with γ-linoleic acid
97. A multicentre double-blind trial of gamolenic acid in diabetic peripheral sensorimotor neuropathy
98. 1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers
99. 1 alpha CD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy
100. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
101. Neurotrophic factors in the treatment of diabetic neuropathy
102. Intracameral recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans
103. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy
104. Stimulations of glucose utilization by thioctic acid in rat diaphragm incubated in vitro
105. The antioxidant α-lipoic acid enhances insulin-stimulated glucose metabolism in insulin resistant rat skeletal muscle
106. Mode of action of lipoic acid in diabetes
107. α-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with Type 2 diabetes
108. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy
109. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multi-center randomized controlled trial (ALADIN Study)
110. Effects of 3-week oral treatment with the antioxidant thioctic acid (α-lipoic acid) in symptomatic diabetic polyneuropathy
111. The effect of alpha-lipoic acid on the neurovascular reflex are in patients with diabetic neuropathy assessed by capillary microscopy
112. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant αlipoic acid
113. Treatment of diabetic polyneuropathy with the anti-oxidant thioctic acid (α-lipoic acid): A two year multi-center randomized double-blind placebo-controlled trial (ALADIN II)
114. Effects of treatment with the anti-oxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multi-center trial (DEKAN-study)
115. Aldose reductase in the BB rat: Isolation, immunological identification and localization in the retina and peripheral nerve
116. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat
117. The antioxidant action of taurine, hypotaurine and their metabolic precursors
118. Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism
119. Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients
120. Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulindeficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol
121. Reversible diabetic nerve dysfunction: Structural correlates to electrophysiological abnormalities
122. Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat: Potential clamp analysis
123. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na, K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat
124. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: Comparison with an aldose reductase inhibitor
125. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine
126. Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat
127. Amelioration of nerve Na(+)-K(+)-ATPase activity independently of myo-inositol level by PGE1 analogue OP-1206.alpha-CD in streptozocin-induced diabetic rats
128. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide
129. Diminished specific activity of cytosolic protein kinase C in sciatic nerve of streptozocin-induced diabetic rats and its correction by dietary myo-inositol
130. Protein kinase C isozyme expression in sciatic nerves and spinal cords of experimentally diabetic rats
131. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats
132. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats
133. Protein kinase C inhibitors decrease hyperalgesia and C-fiber hyperexcitability in the streptozotocin-diabetic rat
134. Alpha-lipoic acid: Effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy
135. Effect of niceritrol on streptozocin-induced diabetic neuropathy in rats
136. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus
137. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging
138. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy
139. Renal catabolism of advanced glycation end products: The fate of pentosidine
140. ε-Amino-lysine-bound glucose in human tissues obtained at autopsy. Increase in diabetes mellitus
141. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface
142. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins
143. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues
144. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury
145. Advanced glycation end products contribute to amyloidosis in Alzheimer disease
146. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
147. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus
148. Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus
149. Glycation of rat sciatic nerve tubulin in experimental diabetic mellitus
150. Glycation of brain action in experimental diabetes
151. Nonenzymatic glycosylation of laminin and laminin peptide CIKVAVS inhibits neurite outgrowth
152. Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats
153. Topology of CNS myelin proteolipid protein: Evidence for the nonenzymatic glycosylation of extracytoplamic domains in normal and diabetic animals
154. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation end products
155. Recognition and uptake of human diabetic peripheral nerve myelin by macrophages
156. ε-carboxymethyllysineprotein adducts, one of advanced glycation endproducts
157. Significance of fructose-induced protein oxidation and formation of advanced glycation end product
158. Role of fructose in glycation and cross-linking of proteins
159. Metabolism of fructose-3-phosphate in the diabetic rat lens
160. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal
161. Role of oxidative stress in diabetic complications, a new perspective on an old paradigm
162. Glycation and inactivation of sorbitol dehydrogenase in normal and diabetic rats
163. Role of polyol pathway in nonenzymatic glycation
164. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat
165. Role of oxidative stress in development of complications in diabetes
166. Hyperglycemic pseudohypoxia and diabetic complications
167. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: Regulation of glutathione synthesis and efflux
168. Oxygen-derived free radicals in postischemic tissue injury
169. Oxidative glycation and free radical production: A causal mechanism of diabetic complications
170. Hydroxyl radical production and autoxidative glycation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and aging
171. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents
172. Superoxide production from nonenzymatically glycated protein
173. Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites
174. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals
175. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
176. Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoie acid in cultured endothelial cells
177. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
178. Receptormediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
179. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
180. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus
181. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy
182. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine
183. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats
184. Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na+,K+)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats
185. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats
186. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy
187. Essential fatty acids in the management of impaired nerve function in diabetes
188. Oxidative stress and abnormal lipid metabolism in diabetic complications
189. Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats
190. Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes
191. Essential fatty acid diet supplementation. Effects on peripheral nerve and skeletal muscle function and capillarization in streptozocin-induced diabetic rats
192. Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids
193. Prostacyclin release in experimental diabetes: Effects of evening primrose oil
194. The effects of evening primrose oil on nerve function and capillarization in streptozotocin-diabetic rats: Modulation by the cyclo-oxygenase inhibitor flurbiprofen
195. Postischemic inhibition of cerebral cortex pyruvate dehydrogenase
196. Neurotrophism in diabetic neuropathy
197. Function and evolution in the NGF family and its receptors
198. Diabetic neuropathy, nerve growth factor and other neurotrophic factors
199. Retrograde axonal transport of transmitter enzymes, fucoselabeled protein, and nerve growth factor in streptozotocindiabetic rats
200. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy
201. Nerve growth factor administration protects against experimental diabetic sensory neuropathy
202. Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor
203. Distribution and ontogeny of SP, CGRP, SOM, and VIP in chick sensory and sympathetic ganglia
204. Neurotrophin 3 supports the survival of developing muscle sensory neurons in culture
205. Lack of neurotrophin-3 leads to deficiencies in the peripheral nervous system and loss of limb proprioceptive afferents
206. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors
207. Target tissue production and axonal transport of neurotrophin-3 are reduced in streptozotocin-diabetic rats
208. Neurotrophic factors in the therapy of diabetic neuropathy
209. Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy
210. Elevated plasma insulin-like growth factor binding protein-1 levels in Type 1 (insulin-dependent) diabetic patients with peripheral neuropathy
211. Reduced insulin-like growth factor-I mRNA content in liver, adrenal glands and spinal cord of diabetic rats
212. Early reduction in insulin-like growth factor gene expression in diabetic nerve
213. Immediate early gene responses are attenuated in diabetic nerve following crush injury
214. Insulin-like growth factors reverse or arrest diabetic neuropathy: Effects on hyperalgesia and impaired nerve regeneration in rats
215. Insulin-like growth factors protect against diabetic neuropathy: Effects on sensory nerve regeneration in rats
216. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy
217. Expression of insulin and IGF-I receptors' mRNAs in peripheral nerve of Type 1 diabetic BB/-W-rat: Effect of C-peptide
218. Insulin-like growth factor-I prevents apoptosis in sympathetic neurons exposed to high glucose
219. Neurons undergo apoptosis in animal and cell culture models of diabetes
220. Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats
221. In vitro studies of the substrates for energy production and the effects of insulin on glucose utilization on the neural components of peripheral nerve
222. Glucose and leucine uptake by dorsal root ganglia is not insulin sensitive
223. Effects of insulin, insulin like growth factor-II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons
224. Evidence for an important role of IGF-I and IGF-II for the early development of chick sympathetic neurons
225. Effects of insulin and insulin-like growth factors on neurofilament mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells
226. Stabilization of tubulin mRNAs by insulin and insulin-like growth factor I during neurite formation
227. Near nerve local insulin prevents conduction slowing in experimental diabetes
228. Molecular basis of insulin action
229. Localization of insulin receptor isoforms in rat peripheral nerve
230. Sodium channels in the cytoplasm of Schwann cells
231. Localization of sodium/potassium adenosine triphosphatase in multiple cell types of the murine nervous system with antibodies raised against the enzyme from kidney
232. Glucose transporters in rat peripheral nerve: Paranodal expression of GLUT1 and GLUT3
233. Ankyrin. A new ankyrin gene with neural-specific isoforms localized at the axonal initial segment and node of Ranvier
234. Paranodin, a glycoprotein of neuronal paranodal membranes
235. Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels
236. Peripheral nerve regeneration
237. C-Peptide induces a concentrationdependent dilation of skeletal muscle arterioles only in presence of insulin
238. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes Type 1
239. Enhancement of insulin receptor activity by C-peptide
240. Long-term effect of C-peptide treatment on type-1 diabetic neuropathy
241. Diabetic polyneuropathy tn Type 2 BBBZDK/Wor rats and comparison with that in Type 1 BB/Wor rats
242. The cellular and physiological actions of insulin in the central nervous system
243. Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry
244. Autoradiographic localization of insulin receptors in rat brain: Prominence in olfactory and limbic areas
245. Regional concentrations of insulin in the rat brain
246. An adipocyte-central nervous system regulatory loop in the control of adipose homeostasis
247. Central insulin and macronutrient intake in the rat
248. Effect of intracerebroventricular insulin infusion on diabetic hyperpliagia and hypo thalamic neuropeptide gene expression
249. Tracking insulin to the mind
250. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats
251. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats
252. Cerebrospinal fluid and plasma insulin levels tn Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype
253. Memory improvement following induced hyperinsulinemia in Alzheimer's disease
254. Is sporadic Alzheimer disease the brain type of noninsulin dependent diabetes mellitus? A challenging hypothesis
255. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons
256. Specific binding of insulin to membranes from dendrodendritic synaptosomes of rat olfactory bulb
257. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses
258. Effect of insulin on central catecholamines
259. Insulin receptors and insulin modulation of norepinephrine uptake in neuronal cultures from rat brain
260. C-Peptide corrects IGFs and prevents apoptosis in Type 1 BB/Wor-rat hippocampus
261. Diabetes mellitus. Pathological changes in the spinal cord and peripheral nerves
262. The neuropathies associated with diabetes mellitus
263. Sensory nerve coduction in patients with diabetes mellitus and controls
264. Peripheral nerve conduction in diabetic neuropathy
265. Schwann-cell abnormalities in diabetic neuropathy
266. The pathology of diabetic neuropathy
267. Diabetische neuropathie. Pathologische anatomie, pathophysiologie und pathogenese auf grund elektronenmikroskopischer untersuchungen
268. Ultrastructural pathology of peripheral nerves in patients with diabetic neuropathy
269. Involvement of automonic nerve fibers in diabetic neuropathy
270. Nerve biopsy and conduction studies in diabetic neuropathy
271. The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy
272. Painful diabetic neuropathy. A morphometric study
273. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. A clinicopathological study
274. Acute painful diabetic neuropathy precipitated by strict glycaemic control
275. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia
276. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy
277. Capillary number and percentage closed in human dibetic sural nerve
278. Pathogenesis of diabetic neuropathy
279. Pattern of myelinated fibre loss in the sural nerve in neuropathy related to Type 1 (insulin-dependent) diabetes
280. Myelinated nerve fibre regeneration in diabetic sensory polyneuropathy: Correlation with type of diabetes
281. Axoglial dysjunction: A novel structural lesion that accounts for poorly-reversible nerve conduction slowing in the spontaneously-diabetic Bio-breeding rat
282. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy
283. Different neuropathic patterns between Type 1 and Type 2 animal models
284. The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later
285. Ischemic mononeuropathy and mononeuropathy multiplex in diabetes mellitus
286. Painful proximal diabetic neuropathy: Inflammatory nerve lesions and spontaneous favorable outcome
287. Nerve biopsy findings in different patterns of proximal diabetic neuropathy
288. Successful treatment of neuropathies in patients with diabetes mellitus
289. The natural history of acute painful neuropathy in diabetes mellitus
290. The morbid anatomy of diabetic neuropathy
291. The natural history of diabetic autonomic neuropathy
292. Myelinated fibres in human paravertebal sympathetic chain: White rami communicantes in alcoholic and diabetic patients
293. The sympathetic chain in patients with diabetic and alcoholic polyneuropathy
294. Effect of diabetes and aging on human sympathetic autonomic ganglia
295. Diabetic neuropathy: A clinical and histological study of the significance of vascular affections
296. Nerve biopsy and Conduction studies in diabetic neuropathy
297. Electron microscopical studies of vessels in diabetic peripheral neuropathy
298. Small vessel disease in progressive diabetic neuropathy associated with good metabolic control
299. Morphometry of endoneurial capillaries in diabetic sensory and autonomic neuropathy
300. Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy
301. Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabes mellitus
302. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity
303. Microangiopathy in human diabetic neuropathy: Relationship between capillary abnormalities and the severity of neuropathy
304. Endoneurial localization of microvascular damage in human diabetic neuropathy
305. Microangiopathy in human diabetic neuropathy
306. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy
307. Endoneurial capillary abnormalities in mild human diabetic neuropathy
308. Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy
309. Enhancement and inhibition of mitogenic action of insulin-like growth factor I by high glucose in cultured bovine retinal pericytes
310. Modification of enzymatic antioxidants in retinal microvascular Cells by glucose or advanced glycation end products
311. Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: A comparative study with retinal capillary endothelial cells
312. Phosphatidylcholine hydrolysis and DNA synthesis in cultured retinal capillary pericytes
313. Observations on small blood vessels of skin in the normal and in diabetic patients
314. Retinal vascular patterns. VI. Mural cell of the retinal capillaries
315. Pericyte degeneration and acellular capillaries are increased in the feet of human diabetic patients
316. Basal lamina: The scaffold for orderly cell replacement. Observations on regeneration of injured skeletal muscle fibers and capillaries
317. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration
318. Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy
319. Insulin receptor in rat peripheral nerve: Its localization and alternatively spliced isoforms
320. Insulin regulates the paracellular permeability of cultured intestinal epithelial cell monolayers
321. Pathology and pathogenetic mechanisms of diabetic neuropathy
322. Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits
323. Axonal dwindling in early experimental diabetes. II. A study of isolated nerve fibres
324. Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats
325. Diabetic neuropathy in STZ-induced diabetic rat and effect of allogeneic islet cell transplantation. Morphometric analysis
326. Neurofilament gene expression: A major determinant of axonal caliber
327. Changes in axon size and slow axonal transport are related in experimental diabetic neuropathy
328. Reversibility and preventability of the decrease in slow axonal transport velocity in experimental diabetes
329. Reduced levels of mRNA encoding endoskeletal and growth-associated proteins in sensory ganglia in experimental diabetes
330. Neurofilament and tubulin gene expression in progressive experimental diabetes: Failure of synthesis and export by sensory neurons
331. Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy
332. Delayed Wallerian degeneration and increased neurofilament phosphorylation in sciatic nerves of rats with streptozocin-induced diabetes
333. Neurofilament protein phosphorylation in spinal cord of experimentally diabetic rats
334. Dystrophic axonal swellings develop as a function of age and diabetes in human dorsal root ganglia
335. Axonal cytoskeletal pathology in aged and diabetic human sympathetic autonomic ganglia
336. Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain
337. Ultrastructural and biochemical characterization of autonomic neuropathy in rats with chronic streptozotocin diabetes
338. Experimental diabetic autonomic neuropathy characterization in streptozotocindiabetic Sprague-Dawley rats
339. Axonal dystrophy in experimental diabetic autonomic neuropathy
340. The effect of pancreatic islet transplantation and insulin therapy on experimental diabetic autonomic neuropathy
341. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats
342. Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin-induced diabetes
343. Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy
344. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats
345. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocindiabetic rats
346. Neurotrophin-3 reverses nerve conduction velocity deficits in streptozotocin-diabetic rats
347. +-channel displacement is associated with nerve-conduction slowing in the chronically diabetic BB/W rat: Prevention by aldose reductase inhibition
348. Imbalances in N-CAM, SAM and polysialic acid may underlie the paranodal ion channel barrier defect in diabetic neuropathy
349. C-Peptide prevents and improves chronic Type 1 diabetic neuropathy in the BB/Wor-rat
350. C-Peptide improves autonomic nerve function in IDDM patients
351. Nerve fiber regeneration following axotomy in the diabetic biobreeding Worcester rat: The effect of ARI treatment
352. Impaired visual evoked potential and primary axonopathy of the optic nerve in the diabetic BB/W-rat
353. The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat
354. Proximal motor neuropathy in the BB-Wistar rat
355. Autonomic neuropathy in BB rats and alterations in bladder function
356. Autonomic neuropathy in BB rat. Assessment by improved NADH oxidase activity in the retina of the BBZ/Wor diabetic rat
357. Diabetic autonomic neuropathy in BB-rat. Ultrastructural and morphometric changes in parasympathetic nerves
358. Neuroaxonal and dendritic dystrophy in diabetic autonomic neuropathy. Classification and topographic distribution in the BB-rat
359. Diabetic autonomic neuropathy. The distribution of structural changes in sympathetic nerves of the BB-rat
360. Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat
361. Insulin attenuates ischemic brain damage independent of its hypoglycemic effect
362. Reduced sensory and motor conduction velocity in 25-week-old diabetic [C57BL/Ks (db/db)] mice
363. Peripheral nerve abnormalities in the diabetic mutant mouse
364. Diabetic neuropathy in the mutant mouse [C57BL/Ks (db/db)]: A morphometric study
365. Peripheral neuropathy in the diabetic mutant mouse. An ultrastructural study
366. Insulin resistance in the GK rat: Decreased receptor number but normal kinase activity in liver
367. Accelerated loss of islet beta cells in sucrose-fed Goto-Kakizaki rats, a genetic model of non-insulin-dependent diabetes mellitus
368. Peripheral neuropathy in selectively-inbred spontaneously diabetic rats: Electrophysiological, morphometrical and freeze-replica studies
369. Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: A genetic model for Type 2 diabetes
370. Does galactose feeding provide a valid model of consequences of exaggerated polyol-pathway flux in peripheral nerve in experimental diabetes?
371. Opposite effects of diabetes and galactosaemia on adenosine triphosphatase activity in rat nervous tissue
372. Dose-dependent alterations in nerve polyols and (Na+,K+)-ATPase activity in galactose intoxication
373. Fine-structural localization of aldose reductase and ouabain-sensitive, K(+)dependent p-nitro-phenylphosphatase in rat peripheral nerve
374. Schwann cell changes induced as early as one week after galactose intoxication
375. Prevention of nerve edema and increased blood-nerve barrier permeability-surface area product in galactosemic rats by aldose reductase or thromboxane synthetase inhibitors
376. Nerve conduction velocity, laser Doppler flow, and axonal caliber in galactose and streptozotocin diabetes
377. Schwann cell changes and demyelination in chronic galactose neuropathy
378. Galactose neuropathy: Impact of chronic endoneurial edema on nerve blood flow
379. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs
380. Peripheral nerve structure and function in long-term galactosemic dogs: Morphometric and electron microscopic analyses
381. Coexistence of nerve conduction deficit with increased Na(+)-K(+)- ATPase activity in galactose-fed mice. Implications for polyol pathway and diabetic neuropathy
382. Galactosemic neuropathy in transgenic mice for human aldose reductase
383. Hypoglycemic peripheral neuropathy in association with insulinoma: Implication of glucopenia rather than hyperinsulinism. Case report and literature review
384. Hypoglycemia from islet cell rumor of pancreas with amyotrophy and cerebrospinal nerve cell changes. A case report
385. Peripheral neuropathy associated with functional islet cell adenomas in SV40 transgenic mice
386. Peripheral nerve pathology in rats with streptozotocin-induced insulinoma
387. Duration and severity of hypoglycemia needed to induce neuropathy
388. The effect of insulin treatment on myelinated nerve fibre maturation and integrity and on body growth in streptozotocin-diabetic rats
389. Degenerative neuropathy in insulin-treated diabetic rats
390. Hypoglycaemic neuropathy in BB/Wor rats treated with insulin implants: Electron microscopic observations
391. Neuropathic changes associated with insulin treatment of diabetic rats: Electron microscopic and morphometric analysis
392. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis)
393. Characterization of peripheral neuropathy in rats with insulinoma induced by streptozotocin and nicotinamide
394. Vascular endothelial growth factor (VEGF) and its receptors
395. Insulin-induced vascular endothelial growth factor expression in retina
396. Diabetic autonomic neuropathy after pancreas and kidney transplantation
397. Improvement in diabetic neuropathy 4 years after successful pancreatic and renal transplantation
398. Role Of C-peptide in human physiology
399. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
400. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group
401. Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-dependent Diabetes Mellitus
402. Effect of angiotensinconverting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: Randomised double-blind controlled trial